How have ABVC shares performed in 2023?

ABVC BioPharma's stock was trading at $6.25 at the beginning of 2023. Since then, ABVC stock has decreased by 80.0% and is now trading at $1.25. View the best growth stocks for 2023 here .

Are investors shorting ABVC BioPharma?

ABVC BioPharma saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 87,700 shares, a decrease of 91.1% from the October 31st total of 984,400 shares. Based on an average daily volume of 2,430,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the shares of the company are sold short. View ABVC BioPharma's Short Interest .

When is ABVC BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our ABVC earnings forecast .

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.90) by $0.40. The firm had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.03 million. ABVC BioPharma had a negative trailing twelve-month return on equity of 348.52% and a negative net margin of 1,611.23%.

When did ABVC BioPharma's stock split?

ABVC BioPharma's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

(ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ABVC BioPharma Stock Price, News & Analysis (NASDAQ:ABVC)

$1.25

-0.10 (-7.41%)

(As of 12/7/2023 ET)

Compare

Today's Range: $1.22
▼
$1.36
50-Day Range: $0.81
▼
$2.02
52-Week Range: $0.67
▼
$18.70

Volume: 437,472 shs
Average Volume: 930,199 shs
Market Capitalization: $9.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Earnings Financials Headlines SEC Filings Short Interest Social Media

About ABVC BioPharma Stock (NASDAQ:ABVC)

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

ABVC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABVC Stock News Headlines

December 7, 2023 | finance.yahoo.com

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

December 5, 2023 | finance.yahoo.com

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | americanbankingnews.com

Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Declines By 91.1%

November 21, 2023 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

November 21, 2023 | marketwatch.com

ABVC BioPharma Shares Rise 11% After U.S. Patent for ADHD Treatment

November 21, 2023 | finance.yahoo.com

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

November 16, 2023 | markets.businessinsider.com

ABVC BioPharma Enters Into Global LIcensing Agreement With AiBtl

December 7, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 16, 2023 | finance.yahoo.com

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

November 15, 2023 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

November 15, 2023 | msn.com

ABVC BioPharma GAAP EPS of -$0.82, revenue of $0.02M

November 15, 2023 | finance.yahoo.com

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

October 27, 2023 | benzinga.com

What's Going On With ABVC Biopharma Stock Friday?

October 26, 2023 | marketwatch.com

Health Care Down Amid Mixed Earnings -- Health Care Roundup

October 26, 2023 | benzinga.com

What In The World Is Going On With ABVC BioPharma Stock?

October 26, 2023 | msn.com

ABVC shares jump after signing licensing deal for CNS drugs

October 26, 2023 | marketwatch.com

ABVC Shares More than Triple on Licensing Deal

October 26, 2023 | finance.yahoo.com

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

October 10, 2023 | msn.com

ABVC BioPharma obtains patent for MDD treatment in Taiwan

October 9, 2023 | markets.businessinsider.com

ABVC BioPharma Gets Taiwanese Patent For Use Of Polygala Extract For Depressive Disorder

October 9, 2023 | finance.yahoo.com

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

August 23, 2023 | finance.yahoo.com

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

August 17, 2023 | markets.businessinsider.com

ABVC BioPharma Enters Into Agreement To Exchange 20% Stake In Real Estate Property Of Zhonghui

August 17, 2023 | finance.yahoo.com

ABVC Executes Cooperation Agreement for Strategic Investments

August 10, 2023 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

August 10, 2023 | finance.yahoo.com

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

See More Headlines

Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/03/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABVC
CUSIP: N/A
CIK: 1173313
Web: www.abvcpharma.com
Phone: (510)-668-0881
Fax: N/A
Employees: 19
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,420,000.00
Net Margins: -1,611.23%
Pretax Margin: -1,493.78%
Return on Equity: -348.52%
Return on Assets: -102.42%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 0.47
Quick Ratio: 0.47

Sales & Book Value

Annual Sales: $970,000.00
Price / Sales: 9.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.99 per share
Price / Book: 1.27

Miscellaneous

Outstanding Shares: 7,230,000
Free Float: 4,412,000
Market Cap: $9.11 million
Optionable: Not Optionable
Beta: 0.46

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Eugene Jiang (Age 37)
Chairman & Chief Business Officer
Comp: $200k
Mr. Leeds Chow (Age 34)
CFO & Principal Accounting Officer
Comp: $130k
Dr. Tsung-Shann Jiang EMBA (Age 69)
Ph.D., Chief Scientific Officer & Director
Comp: $200k
Dr. Uttam Yashwant Patil Ph.D.
Chief Executive Officer

Key Competitors

View All Competitors

ABVC Stock Analysis - Frequently Asked Questions

How have ABVC shares performed in 2023?: ABVC BioPharma's stock was trading at $6.25 at the beginning of 2023. Since then, ABVC stock has decreased by 80.0% and is now trading at $1.25.
View the best growth stocks for 2023 here.
Are investors shorting ABVC BioPharma?: ABVC BioPharma saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 87,700 shares, a decrease of 91.1% from the October 31st total of 984,400 shares. Based on an average daily volume of 2,430,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the shares of the company are sold short.
View ABVC BioPharma's Short Interest.
When is ABVC BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our ABVC earnings forecast.
How were ABVC BioPharma's earnings last quarter?: ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.90) by $0.40. The firm had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.03 million. ABVC BioPharma had a negative trailing twelve-month return on equity of 348.52% and a negative net margin of 1,611.23%.

When did ABVC BioPharma's stock split?: ABVC BioPharma's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
When did ABVC BioPharma IPO?: (ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.
How do I buy shares of ABVC BioPharma?: Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ABVC) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial